Table 6.
Inhibitors targeting PI3K/AKT in clinical trials for cancer treatment
| Inhibitor | Target | Types of cancer |
|---|---|---|
| BEZ235 (Dactolisib) [199, 200] | ATP competitive PI3K α/β/γ/δ | Glioblastoma multiforme, advanced breast cancer |
| BGT226 [201] | ATP competitive PI3K α/β/γ | Solid tumors, advanced breast cancer |
| BKM-120 (Buparlisib) [202] | ATP competitive PI3K α/β/γ/δ | Breast cancer, glioblastoma multiforme |
| GDC-0941 (Pictilisib) [203] | ATP competitive PI3K α/δ | Advanced breast cancer, NSCLC, melanoma, pancreatic cancer |
| SF1126 [204] | ATP competitive PI3K α/β/δ | Advanced solid tumors |
| PX-866 [205] | ATP competitive PI3K α/γ/δ | Ovarian cancer, prostate cancer, glioblastoma multiforme |
| CAL-101 (Idelalisib) [206] | ATP competitive PI3K δ | Chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin’s lymphoma |
| GSK690693 [211] | ATP competitive Akt 1/2/3 | Acute lymphoblastic leukemia |
| AZD5363 [212] | ATP competitive Akt 1/2/3 | Breast cancer, gastric cancer, prostate cancer |
| GSK2110183 (Afuresertib) [213] | ATP competitive Akt 1/2/3 | Multiple myeloma |
| GSK2141795 (Uprosertib) [214] | ATP competitive Akt 1/2/3 | Multiple myeloma |
| GDC-0068 (Ipatasertib) [215] | ATP competitive Akt 1/2/3 | Triple-negative breast cancer |
| MK2206 [217] | Allosteric Akt 1/2/3 | Advanced solid tumor |
| NSC-154020 (Triciribine) [218] | Allosteric Akt 1/2/3 | Hematologic malignancies, NSCLC |